Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial

Bavarian Nordic announced the first stage of a Phase 2 study of its novel, targeted cancer immunotherapy candidate, BN Brachyury in the treatment of advanced chordoma has completed recruitment of the planned 10 patients ahead of schedule.

CStone receives approval in China to start Phase I trial for FGFR4 inhibitor

CStone Pharmaceuticals announced that the National Medical Products Administration recently approved the clinical trial application to start a Phase I clinical trial in China for BLU-554.

Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision

Aldeyra Therapeutics, Inc developing & commercializing next generation medicines to improve the lives of patients with immune-mediated diseases

Manufacturing Consultancy up 150% as Life Sciences prepare for a digital future

Zenith Technologies, a world leader in delivering manufacturing software solutions to the life sciences industry, has seen a 150% rise in demand for its consultancy arm services.

Neovasc Receives Approval to Proceed with Phase 2 of TIARA-II Study from Clinical Regulators

Neovasc Inc ,a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina.

Horizon Discovery Rutgers University to Develop Next Generation Novel Gene Technology

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, announces that it has entered into an exclusive strategic partnership with Rutgers, The State University of New Jersey...

For Advertising Queries:

Please e-mail : kathryn@worldpharmatoday.com
or
call to: + 91 88268 49084

If you like to receive our latest Media Pack / Editorial Calendar please click here

For the latest visit: www.worldpharmatoday.com